Company:  ALLOGENE THERAPEUTICS, IN ... (ALLO)
Form Type:  4
Filing Date:  8/23/2021 
CIK:  0001737287 
Address:  210 EAST GRAND AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 457-2700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$8.00  
Change: 
0.50 (6.67%)  
Trade Time: 
May 27  
Market Cap: 
$1.15B
Trade ALLO now with 

© 2022  
Description of Business
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy, has emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES